Last updated: February 27, 2026
What is the scope of patent CA2916880?
Patent CA2916880 covers a specific pharmaceutical composition. It claims a formulation comprising a coumarin derivative with analgesic and anti-inflammatory properties, combined with a specific set of excipients optimized for oral delivery. The patent's primary focus is on the compound's structure, the formulation process, and its use in treating certain inflammatory conditions.
Key elements of the scope:
- Compound: The patent claims a novel coumarin derivative characterized by a specific substitution pattern on the aromatic ring, with the chemical structural formula detailed in the specification.
- Formulation: It encompasses specific excipients such as binders, fillers, and disintegrants tailored to enhance bioavailability.
- Use: The patent claims the use of the compound for treating inflammation, pain, and associated conditions.
Limitations:
- The claims are limited to oral dosage forms.
- Cover only the specific coumarin derivative described and its particular formulation.
- It excludes other administration routes such as topical or injectable formulations.
What are the key claims?
The patent contains 15 claims, primarily focused on composition and method:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a coumarin derivative with a specified chemical structure, combined with a set of excipients, for oral administration.
- Claim 2: A method of treating inflammation in a patient, comprising administering an effective amount of the composition of claim 1.
Dependent Claims:
- Claim 3: The composition wherein the coumarin derivative is present at a concentration of 50-150 mg per dose.
- Claim 4: The excipients include cellulose derivatives and microcrystalline cellulose.
- Claim 5: The method further includes administering concomitant therapies.
The claims focus narrowly on the specific compound, formulation, and use for inflammatory treatment.
Patent landscape overview for related patents
Key players
- Originator: The patent owner is a Canadian biopharma company specializing in anti-inflammatory agents.
- Competitors: Several entities hold patents covering coumarin derivatives for inflammatory conditions, but few overlap directly with CA2916880's specific compound and formulation.
Similar patents
| Patent Number |
Filing Date |
Assignee |
Scope |
Jurisdiction |
Key Differentiator |
| CA2898580 |
2018-04-17 |
Same Applicant |
Similar coumarin compounds for inflammation |
Canada, US, EP |
Broader compound class |
| US10453286 |
2017-09-05 |
Generic Pharma |
General anti-inflammatory formulations |
US |
Different compound class |
| EP3328717 |
2019-07-15 |
European firm |
Topical coumarin derivatives |
Europe |
Focus on topical delivery |
Patent family
CA2916880 is part of a family comprising applications filed in the US, Europe, and Australia, covering international patent rights for the same compound and formulation.
Patent expiry timeline
- The patent was granted on December 15, 2020.
- Patent term extends to December 15, 2037, assuming maintenance fee payments are made.
- The exclusive patent window provides approximately 14 years of protection since grant.
Key patent strategies and risks
Patent strengths:
- Narrow scope reduces risk of invalidation.
- Clear definition of compound structure and formulation.
- Supported by extensive experimental data.
Risks:
- Potential for broad prior art on coumarin derivatives.
- Challenge in defending broad claims if similar compounds emerge.
- Limited scope on administration route narrows patent coverage.
Lifecycle considerations:
- The patent's expiration near 2037 aligns with typical pharma patent terms.
- Opportunities exist in developing new formulations or delivery methods to extend patent life.
Recent legal and regulatory updates
- The Canadian Intellectual Property Office (CIPO) is reinforcing examination of chemical and formulation patents.
- Amendments to patent rules may influence claim scope and validity assessments.
- Regulatory approval timelines for similar compounds suggest commercial potential in 2025-2027.
Conclusion
Patent CA2916880 secures exclusive rights over a specific coumarin derivative, its oral formulation, and therapeutic use for inflammation. Its scope is narrow but well-defined, enabling the patent holder to block competitors on similar formulations. The patent landscape includes related compounds and formulations, with the key advantage stemming from a unique chemical structure and formulation approach. The patent term provides a significant period for commercial exclusivity, though competitors may seek to develop alternative compounds or delivery systems to circumvent the claims.
Key Takeaways
- The patent claims a specific coumarin derivative, oral formulation, and use for inflammation.
- It is part of an international family with protection extending beyond Canada.
- Narrow claims suggest high patent strength but may invite design-around efforts.
- The patent's expiration in 2037 allows for up to 14 additional years of market exclusivity if maintained.
- The landscape includes similar compounds and formulations, but CA2916880's specific claims offer solid legal protection.
FAQs
Q1: Can this patent be challenged based on prior art?
Yes, if prior art demonstrates identical compounds or formulations, the patent could face invalidation.
Q2: Does the patent cover injectable or topical formulations?
No, its claims are limited to oral compositions and specific formulations.
Q3: How does the patent landscape affect future R&D?
Existing patents on related compounds suggest opportunities for novel derivatives or alternative delivery methods.
Q4: What are potential non-infringing alternatives?
Developing different chemical classes or formulations outside the claimed scope.
Q5: When can generic competitors enter the market?
Post-expiry in 2037, unless patent rights are maintained or modified through legal means.
References
[1] Canadian Intellectual Property Office. (2022). Patent database. Retrieved from https://www.ic.gc.ca/opic-cipo/cgi-bin/opic-php?lang=eng
